In one 40-week Phase 3 trial of 537 adults with type 2 diabetes, back pain was reported by 1%–3% of people taking retatrutide and 7% taking a placebo. That doesn't prove the drug causes or prevents it. But severe belly pain that spreads to your back, back pain with a fever, or new leg weakness needs care today.
There's a twist most pages miss, too. Lilly is now testing retatrutide to treat chronic low back pain. Below: the warning signs, the full trial table, what people report online, and where that back-pain trial stands.
Get emergency help now if back pain comes with new trouble controlling your bladder or bowels, new numbness in your buttocks, inner thighs, or legs, or new leg weakness. Get care today for severe upper-belly pain that spreads to your back, back pain with fever or chills, burning when you pee, or yellow skin or eyes. Took something and don't know what was in it? U.S. Poison Help: 1-800-222-1222, free, 24/7.
When does back pain need care today?
Most back pain is a strained muscle or a cranky joint, and it gets better on its own within weeks. A few patterns are different: pain that starts in the upper belly and spreads to the back, back pain with a fever or burning urine, and back pain with new numbness or weakness all need a clinician soon. Where it hurts, plus what comes with it, tells you how fast to act.
No web page can tell you what's causing your pain. A clinician who examines you can. This table tells you how fast to get to one.
| What you notice | What it can be a sign of | What to do | Source |
|---|---|---|---|
| New trouble controlling bladder or bowels, numbness in the buttocks, thighs, or pelvis, new leg weakness, or trouble walking | Pressure on the nerves in your lower spine | Emergency care now | MedlinePlus |
| Upper-belly pain that won't let up and spreads to your back, often with vomiting, fever, or a racing pulse | Pancreatitis (an inflamed pancreas) | Get care right away | NIDDK; Zepbound label, section 5.5 |
| Ache in the lower back, side (flank), or groin with fever and chills, painful or frequent peeing, or cloudy, dark, or bloody urine | Kidney infection | Get care right away | NIDDK |
| Back or side ache after days of vomiting or diarrhea, peeing much less than usual, dizzy when you stand | Dehydration, which can injure the kidneys | Get care today | Zepbound label, section 5.3 |
| Upper-right belly pain lasting several hours, with fever, yellow skin, tea-colored urine, or pale stools | Gallbladder problem (gallstones or inflammation) | See a doctor right away | NIDDK; Zepbound label, section 5.4 |
| Yellow skin or eyes, dark urine, itchy skin, belly pain, or easy bruising after using a product bought online | Liver injury | Get care today; bring the product | Victoria Department of Health alert |
| Burning, tingling, or sunburn-like soreness on the skin of your back, while the skin looks normal | Dysesthesia, an abnormal skin sensation | Tell your clinician; go sooner if you also have weakness, a rash, or spreading numbness | Lancet, TRANSCEND-T2D-100967-0) |
| A dull ache that's worse when you move and better when you rest, with nothing else on this list | Could be a muscle or joint strain | Watch for changes; contact a clinician if it lasts more than 4 weeks, feels worse than past episodes, or wakes you at night | MedlinePlus |
Here's how that plays out. Say you're ten weeks in. You've been throwing up for two days, you're barely peeing, and both sides of your lower back ache. That's not a "wait and see" back. That's a "get checked today" back, because losing that much fluid can hurt your kidneys.
Now say your back has been stiff since you helped a friend move a couch, and nothing else is going on. That's a different story with a much more ordinary cause.
The pancreatitis, gallbladder, and kidney rows aren't random. The FDA label for Zepbound, a related approved drug, warns about all three. Retatrutide has no FDA label yet, so those are family warnings, not proven retatrutide rates. You'll see what the retatrutide trials themselves recorded next. Our pages on GLP-1 pancreatitis risk, GLP-1 gallbladder risk, and GLP-1s and the kidneys go deeper.
Does retatrutide cause back pain? What the trial recorded
In the one retatrutide trial table we found that lists back pain, it showed up in both the retatrutide groups and the placebo group. The placebo group actually reported it more often. That's a record of what happened during the trial, not proof that retatrutide causes or prevents back pain.
Back pain in TRANSCEND-T2D-1
| Group | People in the group | Reported back pain | Share |
|---|---|---|---|
| Retatrutide 4 mg | 134 | 4 | 3% |
| Retatrutide 9 mg | 133 | 3 | 2% |
| Retatrutide 12 mg | 136 | 2 | 1% |
| Placebo (inactive shot) | 134 | 10 | 7% |
Source: Bajaj HS, et al. TRANSCEND-T2D-1, The Lancet00967-0), published June 6, 2026, Table 2. Adults with type 2 diabetes managed with diet and exercise alone, 40 weeks of treatment. We read the full paper on October 26, 2026.
The dose labels show which trial group each number came from. They are not dosing instructions.
What "reported during a trial" means
Trials write down every health problem that happens while someone is in the study, whether or not the drug caused it. Comparing the drug groups with the placebo group is how researchers look for a pattern. With counts this small, nobody can read your personal risk off this table.
Think of it like a classroom log of everyone who sneezed during a school year. It tells you sneezes happened. It doesn't tell you the new carpet caused them.
Three things to keep straight:
- Back pain landed in this table because the placebo group hit 7%. The table only lists problems reported by 5% or more of any group.
- Fewer cases on retatrutide doesn't make it a back-pain treatment. This trial wasn't built to test that, and the gap is a handful of people.
- This was one group of people. Adults with type 2 diabetes, in a supervised trial, getting the real drug. That's not the same as someone using a vial bought online.
What other retatrutide trials show
Back pain isn't listed among the common adverse events in the other main trial tables and summaries we could check. That does not mean nobody had it: the full supplemental tables may list more events. Stomach problems lead the common-event lists. Some websites say back pain was "higher than placebo" in retatrutide trials, but they give no numbers, and we couldn't verify a table that supports that.
| Trial | People | Back pain listed? | Other findings that matter for back pain | What we read |
|---|---|---|---|---|
| TRANSCEND-T2D-1 (Phase 3, 2026) | 537 | Yes: 1%–3% on retatrutide vs 7% placebo | Gallstones in 1 person on 9 mg and 3 on 12 mg, none on placebo; no confirmed pancreatitis | Full paper |
| Phase 2 type 2 diabetes trial (2023) | 281 | Not in the main list of events affecting 5% or more of all participants; a lower rate is still possible | 1 pancreatitis case and 1 gallbladder inflammation case judged drug-related; urinary tract infections in 5 of 46 people on 12 mg vs 2 of 45 on placebo; the trial's one sudden kidney problem was in the placebo group | Published paper01053-X) |
| Phase 2 obesity trial (2023) | 337 | Not in the main adverse-event table; the supplement was not fully accessible | Stomach side effects were common; the main paper does not supply a back-pain rate or a reliable comparison with placebo | NEJM main trial report |
| TRIUMPH-1 through TRIUMPH-4 (Phase 3) | 5,885 | Not listed in Lilly's common-event summaries; full supplementary back-pain counts remain unverified | The published main trial reports and company summaries emphasize nausea, diarrhea, constipation, vomiting, and dysesthesia | Our side-effects review |
Want every side effect by dose? See our full retatrutide side-effects review and our guide to reading side-effect rates.
Is it your back, or your skin?
Retatrutide has a known side effect called dysesthesia: burning, tingling, or sore, over-sensitive skin, even when the skin looks normal. At the 12 mg dose, reported rates ranged from 4.4% to 20.9% across five separate Phase 3 trials. That is a range across different studies, not one pooled rate. If the soreness is on the surface rather than deep in your muscles or spine, this may be what you're feeling.
In TRANSCEND-T2D-1, dysesthesia was reported by 6 people on 4 mg (4%), 3 on 9 mg (2%), and 6 on 12 mg (4%). Nobody on placebo reported it. The paper doesn't say where on the body those feelings were.
A quick way to describe it to your clinician:
- Does light touch, a waistband, or a bra strap hurt?
- Does the skin look normal?
- Is it on one side or both?
- Do you also have weakness, a rash, or numbness that's spreading?
Those answers help them sort a skin-nerve feeling from a deep muscle, spine, or organ problem. More in our guide to retatrutide skin sensitivity.
Why could back pain happen while using retatrutide?
No study has shown that retatrutide itself causes back pain. But a few things that can happen on drugs in this family can lead to pain in or near the back. Knowing them helps you spot the ones that need care.
- Dehydration. Vomiting and diarrhea drain fluid fast. The Zepbound label says most kidney injuries reported after approval happened in people who got dehydrated that way.
- Gallstones. The Zepbound label says gallbladder problems were linked with weight reduction, and TRANSCEND-T2D-1 recorded gallstones in 4 people on retatrutide and none on placebo.
- Urinary infections. In the small Phase 2 diabetes trial, these were more common at 12 mg than on placebo. An infection that reaches the kidneys can cause back or side pain with fever.
- Muscle loss (an open question). Weight loss on GLP-1 drugs includes some muscle. Weaker back muscles are linked with back pain in research, but no study shows this happening with retatrutide. See retatrutide muscle loss and how to get enough protein on a GLP-1.
- What's actually in the vial. Lilly says illegal products sold as retatrutide may have the wrong ingredient, the wrong amount, or contaminants. Nothing on this page can tell you what's in yours. See how to avoid fake GLP-1 medications.
You'll see other sites blame "posture changes" or "disc dehydration." We couldn't find retatrutide evidence for either, so we're not repeating them.
What about the back pain people post about online?
An October 2026 study in JAMA Network Open looked at Reddit posts from people who said they were using retatrutide bought outside trials. Back pain came up for 45 of 7,823 people who described symptoms, about 0.6%. That number can't tell you how often the real drug causes back pain.
The researchers started with 148,640 posts and comments from 38,936 Reddit users in 27 communities, written from May 2021 through December 2025. Of those, 13,589 users described current use. The 7,823 figure is the smaller group whose posts mentioned at least one symptom the researchers could classify.
They were clear about the limits. They couldn't check what was in anyone's product, the dose, other drugs, or medical history. People with bad experiences may post more. The study can't measure how common a symptom is or what caused it. (Sehgal et al., JAMA Network Open, Oct. 14, 2026)
That's why the three kinds of "retatrutide back pain" information online need to stay separate:
| Question | What the evidence is | What it can and can't tell you |
|---|---|---|
| Did people in a trial report back pain? | TRANSCEND-T2D-1: 1%–3% on retatrutide, 7% on placebo | Shows it happened during treatment; doesn't prove cause or predict your risk |
| Do people using online products post about back pain? | JAMA Network Open: 45 of 7,823 selected Reddit users (0.6%) | Not a medical rate; product contents unknown |
| Can retatrutide treat chronic back pain? | TRIUMPH-7 is testing it; no results yet | A research question, not a proven benefit |
Is retatrutide being tested to treat back pain?
Yes. Lilly's TRIUMPH-7 trial is testing retatrutide against a placebo in adults with overweight or obesity and chronic low back pain. Its enrollment goal is 586 people. Enrollment is closed, the study's estimated completion is September 2027, and no results have been posted.
| TRIUMPH-7 at a glance | Details |
|---|---|
| Trial ID | NCT07035093 (Lilly study J1I-MC-GZQD) |
| Design | Phase 3, randomized, double-blind, placebo-controlled |
| Size | 586 people (enrollment goal) |
| Who could join | Adults 18+ with a BMI of 27 or higher, long-lasting back pain mainly in the low back (it can spread only as far as the upper legs), and at least one failed diet attempt |
| Who couldn't | Anyone with any type of diabetes; a spine steroid or botox shot within 1 year; a trigger-point shot within 6 months; a weight change of more than 11 pounds in the 90 days before screening; weight-loss drugs within 90 days; past or planned weight-loss surgery |
| Main measure | Change in average back-pain score on a 0–10 scale |
| Time in the trial | About 80 weeks |
| Started | May 29, 2025 |
| Primary study completion | September 2027 (estimated; results may be released later) |
| Status | Lilly: Completed Enrollment. ClinicalTrials.gov: Active, not recruiting (checked October 26, 2026) |
Sources: Lilly trial page and ClinicalTrials.gov, both checked October 26, 2026. Some trial-listing websites still show this study as "recruiting." Lilly's own page says enrollment is complete.
What that means for you:
- You can't join this one. Enrollment is closed. For other studies, see our retatrutide clinical trials tracker.
- Don't expect a back-pain approval soon. Lilly's stated plan is to file first for obesity, knee arthritis pain, and sleep apnea, with early 2027 as its target. Back pain would need TRIUMPH-7's results first. See retatrutide news today for the latest on filing.
Could weight loss ease back pain? What the evidence says so far
The best clue comes from knees, not backs. In Lilly's TRIUMPH-4 trial of people with knee arthritis, retatrutide cut knee-pain scores far more than placebo. Whether that carries over to the lower back is exactly what TRIUMPH-7 is testing.
| Evidence | What it found | How much it tells you |
|---|---|---|
| TRIUMPH-4, retatrutide for knee arthritis (445 people, 68 weeks) | Knee-pain score fell by up to 4.5 points (75.8%) vs 2.4 points (40.3%) on placebo; the percentages came from an analysis added afterward (Lilly) | Strong for knees. A knee isn't a spine |
| Small study of other GLP-1 drugs for back pain (35 adults on tirzepatide or semaglutide) | Median pain-severity score fell from 4.8 to 2.0 over 12 months (study published in Pain Medicine, September 2026; open earlier manuscript) | An early hint. Peer reviewed, but small, with no comparison group; it does not show the medicines caused the improvement |
| Semaglutide back-pain trial at Washington University | A placebo-controlled trial, with recruitment expected to start in early 2027 (WashU) | No results yet |
For the knee story in full, see retatrutide for knee osteoarthritis.
Is retatrutide legal to buy?
No, not as a medicine you can buy. Retatrutide isn't approved by the FDA or any other regulator, and the FDA says it can't be used in compounding under federal law. Lilly says retatrutide sold to consumers outside its authorized research is illegal. A narrowly restricted expanded-access program also exists, but it is not retail access.
The FDA has also warned companies that sell retatrutide labeled "for research purposes" or "not for human consumption" while giving buyers dosing instructions. It urges people not to buy them, because no one has checked their quality. (FDA, content current as of October 1, 2026; Lilly, updated September 2026)
The exception is very narrow: Lilly has a registered expanded-access program for certain adults with a BMI of at least 35, at least two serious or life-threatening obesity-related complications, no satisfactory approved treatment, and no way to join an applicable trial. The treating doctor must request it from Lilly; Lilly decides case by case. It's not a store. Our guide to getting retatrutide legally explains who might qualify.
What to tell your clinician
Your clinician doesn't need you to know the cause. They need the details: where it hurts, when it started, what else is going on, and exactly what you've been taking. Leaving out where a product came from only makes their job harder.
If you've been using something bought online, you can say this word for word:
"I've been using a product sold as retatrutide. I'm not sure what was in it. I started around [date], last took about [amount] on [date], and my back pain started [when]."
Bring or note:
- Where the pain is, what it feels like (deep ache, sharp, burning skin), and whether it's getting worse
- Any fever, vomiting, diarrhea, burning when you pee, or changes in urine color
- Any numbness, weakness, or trouble walking
- The vial, box, label, lot number, and receipt, or photos of them
- Every other medicine, supplement, or peptide you use
After you've gotten care, you can report what happened to the FDA through MedWatch. Patients can file directly. Our guide on talking to your doctor about GLP-1s has more.
Want weight-loss treatment you can legally get?
If your pain has been checked out and you still want help with your weight, you don't have to use an unapproved product. FDA-approved GLP-1 medicines, including Zepbound, Wegovy, and Foundayo, are available by prescription today. Which one fits depends on your health, your insurance, where you live, whether you'd rather take a shot or a pill, and your budget.
This is a separate decision from your back pain. A different medicine isn't a back-pain fix, and only a clinician can say whether you qualify.
A few quick questions can point you in the right direction:
- Is your BMI 30 or higher, or 27 or higher with a weight-related health condition?
- Do you know whether your insurance covers weight-loss medicine?
- Would you rather have a weekly shot or a daily pill?
"Not sure" is a fine answer to all three. If you've dealt with the pain question and want to compare legal, clinician-supervised options, The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It's free, takes about 2 minutes, and needs no signup. It isn't a symptom checker, it can't promise approval or coverage, and it won't match you to retatrutide or any unapproved seller.
Prefer to read first? Our list of FDA-approved alternatives to retatrutide compares them side by side.
How we checked this
We went back to the original trial tables, the peer-reviewed social-media study, the FDA's own statements, the official trial records, and NIH patient guidance. We kept three things separate on purpose: what happened in a trial, what people post online, and what a new trial is testing.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
What we actually verified (October 2026)
- Read in full: the TRANSCEND-T2D-1 paper and its Table 2 (The Lancet00967-0)) and the JAMA Network Open research letter. Checked published study records and main safety results: the Phase 2 type 2 diabetes study (The Lancet01053-X)), the Phase 2 obesity trial, and the small back-pain study now published in Pain Medicine (September 15, 2026).
- Checked at the source: FDA's unapproved GLP-1 page; Lilly's retatrutide and expanded-access pages; the registered expanded-access program; TRIUMPH-7 on Lilly's site and ClinicalTrials.gov; the Zepbound label (revised February 2026); NIDDK pages on pancreatitis, kidney infection, and gallstones; MedlinePlus on low back pain; the Victoria health alert; and the Poison Help number.
- Rechecked October 26: the five-trial dysesthesia range (first checked August 8, 2026) and Lilly's plan to file in the first quarter of 2027 (previously checked October 14, 2026). Those filing plans are not an FDA approval.
- Could not confirm: back-pain counts in the Phase 2 obesity supplement or in the complete supplementary safety tables for TRIUMPH-1 and TRIUMPH-2. The main published reports do not provide those rates. We have not assumed they were zero.
- We did not: test any product, link to any seller, give dosing advice, or have a medical reviewer review this version.
Learn more about how we evaluate evidence and treatment paths.
Retatrutide back pain FAQ
When does soreness after injection day go away?
The retatrutide trials don't publish a personal timeline for aches, so no one can promise a number of days. Most everyday back pain improves within 4 to 6 weeks, and MedlinePlus says to contact a clinician if it lasts more than 4 weeks. Get care sooner for anything on the warning-sign list, and remember that burning skin can be dysesthesia rather than back pain.
Is my back pain actually kidney pain?
You can't tell from location alone, and neither can a web page. Kidney infection can come with fever, chills, painful or frequent peeing, or cloudy, dark, or bloody urine, and it needs care right away. A back ache after days of vomiting or diarrhea also needs a same-day check, because dehydration can injure the kidneys.
Does retatrutide cause lower back pain?
There's no proof it does. In TRANSCEND-T2D-1, back pain was reported by 1%–3% of people on retatrutide and 7% on placebo over 40 weeks. That shows back pain happened during the trial, not that the drug caused it.
How many people got back pain in the retatrutide trials?
In TRANSCEND-T2D-1, 4 of 134 people on 4 mg, 3 of 133 on 9 mg, and 2 of 136 on 12 mg reported back pain, compared with 10 of 134 on placebo. In the Phase 2 diabetes and obesity trials, the main safety tables did not report a back-pain rate. We could not check all supplementary safety tables, so "not listed" does not mean nobody reported it.
Can retatrutide cause pancreatitis?
A small number of pancreatitis cases happened in the Phase 2 retatrutide trials, and the study doctor judged one of them drug-related; TRANSCEND-T2D-1 had no confirmed cases. Labels for approved drugs in this family warn about it, describing severe belly pain that can spread to the back. If you have that kind of pain, especially with vomiting, get care right away.
Is retatrutide being tested to treat back pain?
Yes. Lilly's TRIUMPH-7 trial is testing retatrutide against placebo for chronic low back pain in adults with overweight or obesity. Its enrollment goal is 586, enrollment is complete, and primary study completion is estimated for September 2027. No results have been posted yet.
Is retatrutide FDA-approved or legal to compound?
No. Retatrutide isn't approved anywhere, and the FDA says it can't be used in compounding under federal law. A "research use only" label doesn't make a product legal or safe to inject.
Are Reddit back-pain numbers the same as trial numbers?
No. The JAMA Network Open study found back pain in 45 of 7,823 selected Reddit users who described symptoms, but no one could check what was in their products. Trial numbers come from people given a verified drug or placebo under supervision, so the two can't be compared.
Sources
All checked October 26, 2026, unless noted.
- Bajaj HS, et al. TRANSCEND-T2D-1. The Lancet, published online June 6, 2026. doi.org/10.1016/S0140-6736(26)00967-000967-0)
- Rosenstock J, et al. Retatrutide Phase 2 trial in type 2 diabetes. The Lancet, 2023. doi.org/10.1016/S0140-6736(23)01053-X01053-X)
- Sehgal NKR, et al. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Network Open, October 14, 2026. jamanetwork.com
- Eli Lilly. TRIUMPH-7 trial page. trials.lilly.com
- ClinicalTrials.gov. NCT07035093. clinicaltrials.gov
- U.S. FDA. Zepbound prescribing information, revised February 2026. accessdata.fda.gov
- U.S. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current October 1, 2026. fda.gov
- Eli Lilly. What to know about retatrutide, updated September 2026. lilly.com
- NIDDK. Symptoms & Causes of Pancreatitis. niddk.nih.gov
- NIDDK. Symptoms & Causes of Kidney Infection. niddk.nih.gov
- NIDDK. Symptoms & Causes of Gallstones. niddk.nih.gov
- MedlinePlus. Low back pain — acute. medlineplus.gov
- Eli Lilly. TRIUMPH-4 results, December 11, 2025. investor.lilly.com
- Benedict B, et al. Impact of GLP-1 receptor agonists on chronic low back pain in patients with obesity: a prospective pilot cohort study. Pain Medicine, published online September 15, 2026. doi.org/10.1093/pm/pnag121. Earlier open manuscript.
- Washington University School of Medicine. Semaglutide trial for chronic low back pain announcement. neurosurgery.wustl.edu
- Victoria Department of Health. Toxicity linked to unapproved peptide product labelled Retatrutide, June 19, 2026 (originally checked August 8; rechecked October 26, 2026). health.vic.gov.au
- U.S. FDA. MedWatch. fda.gov
- Jastreboff AM, et al. Retatrutide Phase 2 obesity trial, main adverse-event table. New England Journal of Medicine, June 26, 2023. doi.org/10.1056/NEJMoa2301972
- ClinicalTrials.gov. Pre-approval Expanded Access of Retatrutide, NCT07629401, updated August 6, 2026. clinicaltrials.gov
- Eli Lilly. Expanded Access Policy. lilly.com
- U.S. HRSA. Calling Poison Help. poisonhelp.hrsa.gov